Hydroxychloroquine in IgA nephropathy: a systematic review

BACKGROUND: Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. METHODS: Electronic da...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefan, Gabriel, Mircescu, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604447/
https://www.ncbi.nlm.nih.gov/pubmed/34779707
http://dx.doi.org/10.1080/0886022X.2021.2000875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604447/
https://www.ncbi.nlm.nih.gov/pubmed/34779707
http://dx.doi.org/10.1080/0886022X.2021.2000875

Ejemplares similares